All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 14 March 2024
On Thursday, March 14, 2024, Phase Holographic Imaging PHI AB (publ), held an extraordinary general meeting. The following resolutions were passed at the meeting.
PostNews: Press Release

Shaping the future of Regenerative Medicine – PHI’s vision for QPI in Cell Therapy Manufacturing
PHI presents a comprehensive opinion piece detailing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.
PostNews: Press Release

New Distributor Partner Manager at Altium set to enhance global sales for PHI
PHI is conveying the news that its global distributor, Altium ., has appointed a PHI-dedicated distributor partner manager. This strategic step is set to significantly enhance the reach and sales performance of PHI’s HoloMonitor technology on a global scale.
PostNews: Press Release
Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 14 March 2024
Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an extraordinary general meeting on 14 March 2024 at 10.00 am at the Company’s premises, Skiffervägen 48 in Lund.
PostNews

BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
PostNews: Press Release

PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024
PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.

No Blood, No Tumor
Scientists at Boston Children’s Hospital have used HoloMonitor to study living bone cancer cells. By studying their dynamics, they have successfully for the first time distinguished aggressive bone cancer cells that promote blood vessel formation from the harmless counterparts that do not promote blood vessel formation.

Big Data, Fewer Cells
Scientists at Holographic Imaging Cytometry Program of Excellence at Northeastern University have developed a method to compare time series data of drug treated cells with untreated cells.

3D Culture
Using HoloMonitor and a public domain image processing software called Image J, the researchers from Northeastern University have developed a method for cell experiments based on cells cultured in a 3-dimensional collagen gel. They show that this new method is clearly superior to conventional methods, based on cells cultured on a 2-dimensional.

Big Pharma, Big Data
Imaged-based time-lapse cytometers, as our HoloMonitor, creates huge amounts of information on how cells interact and multiply over long time periods. Combined with Big Data technology, such novel instrumentation will provide cell biologists and the pharmaceutical industry with a game changing new tool to better understand complex cellular interactions and through this hopefully cure cancer.